US 12,215,150 B2
Anti-SLC34A2 monoclonal antibodies and uses thereof
Runsheng Li, Shanghai (CN); Wentao Huang, Shanghai (CN); and Yifan Li, Shanghai (CN)
Assigned to LANOVA MEDICINES DEVELOPMENT CO., LTD., Shanghai (CN)
Filed by LANOVA MEDICINES DEVELOPMENT CO., LTD., Shanghai (CN)
Filed on May 6, 2024, as Appl. No. 18/656,092.
Application 18/656,092 is a continuation of application No. PCT/CN2023/101761, filed on Jun. 21, 2023.
Claims priority of application No. PCT/CN2022/100315 (WO), filed on Jun. 22, 2022.
Prior Publication US 2024/0301052 A1, Sep. 12, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01)] 17 Claims
 
1. An antibody or fragment thereof having binding specificity to a human solute carrier 34 A2 (SLC34A2) protein, wherein the antibody or fragment thereof comprises a heavy chain variable region comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3 and a light chain variable region light chain comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein:
(a) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 51,
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 52 or 57,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 53,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 54,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 55, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 56,
(b) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 66,
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 67 or 72,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 68,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 69,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 70, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 71,
(c) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 81,
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 82 or 87,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 83,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 84,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 85, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 86, or
(d) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 96,
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 97 or 102,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 98 or 103,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 99,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 100, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 101.